United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $530.11, for a total transaction of $5,036,045.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $171,990,478.73. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

UTHR opened at $515.50 on Wednesday. The business’s 50-day simple moving average is $538.63 and its 200-day simple moving average is $535.46. United Therapeutics Corporation has a one year low of $292.34 and a one year high of $609.35. The stock has a market capitalization of $22.11 billion, a P/E ratio of 18.44, a price-to-earnings-growth ratio of 1.79 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $6.41 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.32 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in United Therapeutics in the second quarter worth $2,868,735,000. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Wellington Management Group LLP grew its position in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.